{"news_desk": "Business", "print_page": "", "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"original": "By DAVID GELLES", "person": [{"rank": 1, "role": "reported", "firstname": "David", "organization": "", "lastname": "GELLES"}]}, "abstract": null, "type_of_material": "News", "word_count": "699", "lead_paragraph": "Some analysts believe Valeant remains better positioned to take over Salix, given potential shareholder votes, an F.D.A. review and financial issues.", "pub_date": "2015-03-13T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "Uncertainty Weighs on Endo\u2019s Higher Bid for Salix Pharmaceuticals", "content_kicker": "News Analysis", "kicker": "News Analysis"}, "snippet": "Some analysts believe Valeant remains better positioned to take over Salix, given potential shareholder votes, an F.D.A. review and financial issues.", "multimedia": [], "web_url": "http://www.nytimes.com/2015/03/13/business/dealbook/uncertainty-weighs-on-endos-higher-bid-for-salix-pharmaceuticals.html", "keywords": [{"rank": "1", "is_major": "N", "value": "Mergers, Acquisitions and Divestitures", "name": "subject"}, {"rank": "2", "is_major": "N", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "3", "is_major": "N", "value": "Salix Pharmaceuticals Ltd", "name": "organizations"}, {"rank": "4", "is_major": "N", "value": "Valeant Pharmaceuticals International Inc", "name": "organizations"}, {"rank": "5", "is_major": "N", "value": "Endo International PLC", "name": "organizations"}, {"rank": "6", "is_major": "N", "value": "Paulson & Co", "name": "organizations"}, {"rank": "7", "is_major": "N", "value": "Food and Drug Administration", "name": "organizations"}], "blog": [], "_id": "5501c82038f0d8082e60cece", "source": "The New York Times"}